TrialA Study of Barzolvolimab in Patients With Atopic Dermatitis
Trial details
- Registry ID
- NCT06727552
- Phase
- Phase 2
Drug research
Barzolvolimab
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as CDX-0159
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Barzolvolimab in Patients With Atopic DermatitisNCT06727552 | Celldex Therapeutics | Phase 2 | Active not recruiting | 2026-05-06Actual |
| A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)NCT07266402 | Celldex Therapeutics | Phase 3 | Recruiting | 2028-06Estimated |
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
Trial details
- Registry ID
- NCT07266402
- Phase
- Phase 3
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |